Skip to content
2000
Volume 26, Issue 33
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Background: The possibilities of treatment for oncological diseases are growing enormously in the last decades. Unfortunately, these developments have led to the onset of resistances with regards to the new treatments. This is particularly true if we face with the therapeutic field of Tyrosine Kinase Inhibitors (TKIs). This review gives an overview of possible TKI resistances that can occur during the treatment of an oncologic diesease and available strategies that can be adopted, taking cues from a successful example such as CML. Methods: We performed a literature search for peer-reviewed articles using different databases, such as PubMed and Scopus, and exploiting different keywords and different logical operators. Results: 68 papers were included in the review. Twenty-four papers give an overview of the causes of TKIs resistances in the wide oncologic field. The remaining papers deal CML, deeply analysing the TKIs Resistances present in this pathology and the strategies adopted to overcome them. Conclusion: The aim of this review is to furnish an overview and a methodological guideline for the approach and the overcoming of TKIs Resistances.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867325666180607092451
2019-10-01
2025-06-17
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867325666180607092451
Loading

  • Article Type:
    Review Article
Keyword(s): asciminib; Bcr-Abl; Cancer; chronic myeloid leukemia; imatinib; kinase; resistance; TKI
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test